Evidence for the clinical use of tumour markers

Annals of Clinical Biochemistry

Volumn 41, Issue 5, 2004, Pages 370-377

  Duffy, Michael J ^a,b  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b Dublin Molecular Medicine Centre   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CHORIONIC GONADOTROPIN; CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; LACTATE DEHYDROGENASE; METHOTREXATE; PROSTATE SPECIFIC ANTIGEN; TAMOXIFEN; TRASTUZUMAB; TUMOR MARKER; UROKINASE;

BREAST CANCER; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER SCREENING; COLORECTAL CANCER; GERM CELL TUMOR; HUMAN; ONCOGENE; ONCOGENE NEU; OVARY CANCER; PATIENT MONITORING; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; REVIEW; TREATMENT OUTCOME;

CLINICAL TRIALS; EVIDENCE-BASED MEDICINE; HUMANS; NEOPLASMS; PREDICTIVE VALUE OF TESTS; TUMOR MARKERS, BIOLOGICAL;

EID: 4644336962     PISSN: 00045632     EISSN: None     Source Type: Journal    
DOI: 10.1258/0004563041731529     Document Type: Review

References (51)

1. Duffy MJ. Clinical uses of tumor markers: a critical review. Crit Rev Clin Lab Sci 2002; 38: 225-62
2. Hayes D, Bast RC, Desch CE, Fritsche H, Kemeny NE, Jessup JM, et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Instit 1996; 88: 1456-66
3. Anonymous. Carcinoembryonic antigen: its role as a marker in the management of cancer, Summary of an NIH consensus statement. Lancet 1981; 282: 373-5
4. Duffy MJ. CEA as a marker for colorectal cancer: is it clinically useful. Clin Chem 2001; 34: 347-52
5. Bruinvels DJ, Stiggelbout AM, Kievit J, van Houwelingen HC, Habbema DF, van de Velde CH. Follow-up of colorectal cancer: a meta-analysis. Ann Surg 1994; 219: 174-82
6. Rosen M, Chan L, Beart RW, Vukasin P, Anthone G. Follow-up of colorectal cancer: a meta analysis. Dis Colon Rectum 1998; 41: 1116-26
7. Renehan AG, Egger M, Saunders MP, O'Dwyer ST. Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. BMJ 2002; 324: 813-6
8. Anonymous. Clinical practice guidelines for use of tumor markers in breast and colorectal cancer. J Clin Oncol 1996; 14: 2843-77
9. Duffy MJ, van Dalen A, Haglund C. Clinical utility of biochemical markers in colorectal cancer: European Group on Tumor Markers (EGTM) guidelines. Eur J Cancer 2003; 39: 718-27
10. International Germ Cell Cancer Collaborative Group. International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997; 15: 594-603
11. Green FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, et al. AJCC Cancer Staging Manual. 6th Edition. New York: Springer-Verlag 2000
12. Sturgeon C. Practical guidelines for tumor marker use in the clinic. Clin Chem 2002; 48: 1151-9
13. Fleisher M, Dnistrian AM, Sturgeon CM, Lamerz R, Wittliff JL. Practice guidelines and recommendations for use of tumor markers in the clinic. In: Diamindis EP, Fritsche H, Scharwtz MK, Chan DW, eds, Tumor markers, physiology, pathobiology, technology and clinical applications. Chicago: AACC Press 2002: 33-63
14. Bosl GJ, Motzer RJ. Testicular germ-cell cancer. N Eng J Med 1977; 337: 24251
15. Stenman U-H, Alfthan H. Markers for testicular cancer. In: Diamindis EP, Fritsche H, Scharwtz MK, Chan DW, eds, Tumor markers, physiology, pathobiology, technology and clinical applications. Chicago: AACC Press 2002: 351-9
16. Segal R, Lukka H, Klotz LH, et al. Genitourinary cancer disease site group, Cancer Care Ontario Practice Guidelines Initative (CCOPGI). Surveillance programs for early stage non-seminomatous testicular cancer: a practice guideline. Can J Urol 2001; 8: 1184-92
17. Bunting PS. Screening for prostate cancer with prostate specific antigen: beware of the biases. Clin Chim Acta 2002; 315: 71-97
18. De Koning HJ, Auvinen A, Berenguer Sanchez A, Calais da Silva F, Ciatto S, Denis L, et al. Large-scale randomised prostate cancer screening trials: program performances in the European randomised screening for prostate cancer trial and the prostate, lung, colorectal and ovary cancer trial. Int J Cancer 2002; 97: 237-44
19. Gohagan JK, Prorok PC, Kramer BS, Hayes RB, Cornett JE. The prostate, lung, colorectal and ovarian cancer screening trial of the National Cancer Institute. Cancer 1995; 75: 1869-73
20. Von Eschenbach A, Ho R, Murphy GP, Cunningham M, Lins N. American Cancer Society guideline for the early detection of prostate cancer; update 1997. CA Cancer J Clin 1997; 47: 261-4
21. US Preventive Services Task Force. Screening for prostate cancer: recommendations and rationale. Ann Int Med 2002; 137: 915-6
22. Semjonow A, Albrecht W, Bialk P, Gerl A, Lamerz R, Schmid H-P, et al. Tumor markers in prostate cancer: EGTM recommendations. Anticancer Res 1999; 19: 2785-820
23. Berek JS, Bertelsen K, du Bois A, Brady MF, Carmichael J, Eisenhauer EA, et al. Advanced epithelial ovarian cancer: 1998 consensus statements. Ann Oncol 1999; 10(Suppl 1): S87-S92
24. Bast RC, Xu F-J, Yu Y-H, Barnhill S, Zhang Z, Mills GB. CA 125: the past and the future. Int J Biol Markers 1998; 13: 179-87
25. Tuxen MK, Soletormos G, Dombernowsky P. Tumor markers in the management of patients with ovarian cancer. Cancer Treat Rev 1995; 21: 215-43
26. Rustin GJ, Nelstrop AE, McClean P, Brady MF, McGuire WP, Hoskins WJ, et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol 1996; 14: 1545-51
27. Rustin GJ. Use of CA 125 to assess response to new agents in ovarian cancer trials. J Clin Oncol 2003; 21(Suppl): 187-93
28. Rustin GJ, Nelstrop AE, Bebtzen SM, Bond SJ, McClean P. Selection of active drugs for ovarian cancer based on CA 125 and standard response rates in Phase II trials. J Clin Oncol 2000; 18: 1733-9
29. Guppy AE, Rustin GJS. CA 125 response: can it replace the traditional response criteria in ovarian cancer. Oncologist 2002; 7: 437-43
30. Duffy MJ. CA 15-3 and related mucins as circulating markers in breast cancer. Ann Clin Boichem 1999; 36: 579-86
31. Cheung K, Graves CRL, Robertson JFR. Tumour marker measurements in the diagnosis and monitoring of breast cancer. Cancer Treat Rev. 2000; 26: 91-102
32. Sauer H. Significance of tumor markers during the follow-up of women without symptoms after treatment of primary breast cancer. Anticancer Res 1997; 17: 3059-62
33. Nicolini A, Anselmi L, Michelassi C, Carpi A. Prolonged survival by early salvage treatment of breast cancer patients: a retrospective 6-year study. Br J Cancer 1997; 76: 1106-11
34. Kovner F, Merimsky O, Hareuveni M, Wigler N, Chaitchik S. Treatment of disease-negative but mucin-like carcinoma-associated antigeb-positive breast cancer patients with tamoxifen: preliminary results of a prospective controlled randomised trial. Cancer Chemother Pharmacol 1995; 35: 80-3
35. Bast RC, Ravdin P, Hayes DF, Bates S, Fritsche H Jr, Jessup JM, et al. 2000 Update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19: 1865-78
36. McGuire WL, Carbone PP, Sears ME, Escher GC. Estrogen receptors in human breast cancer: an overview: In: WL McGuire, PP Carbone and EP Vollner, eds, Estrogen Receptors in Human Breast Cancer. New York: Raven Press 1975: 1-8
37. Early Breast Cancer Trialist's Collaborative Group. Tamoxifen for early breast cancer: an overview of randomized trials. Lancet 1998; 351: 1451-67
38. Hayes DF, Trock B, Harris AL. Assessing the clinical impact of prognostic factors: when is 'statistically significant' clinically useful. Breast Cancer Res Treat 1998; 52: 305-19
39. Molina R, Duffy MJ, Aronsson AC, Lamerz R, Stieber P, van Dalen A. Tumor Markers in Breast Cancer, EGTM recommendations. Anticancer Res 1999; 19: 2785-820
40. Revillion F, Bonneterre J, Peyrat JP. ErbB-2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 1998; 34: 791-808
41. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA. Nonclinical studies addressing the mechanism of action of Trastuzumab (Herceptin). Sem Oncol 1999; 26(Suppl 12): 60-70
42. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpressed HER-2. N Eng J Med 2001; 344: 783-92
43. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2 overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 719-26
44. Carney WP, Neuman R, Lipton A, Leitzel K, Ali S, Price CP. Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer. Clin Chem 2003; 49: 1579-98
45. Duffy MJ. Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies. Clin Chem 2002; 48: 1194-7
46. o Study Group. Randomized adjuvant chemotherapy trial in high-risk node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Instit 2001;93:913-20
47. Look MP, van Putten WLJ, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, et al. Pooled analysis of prognostic impact of tumor biological factors uPA and PAI-1 in 8377 breast cancer patients. J Natl Cancer Instit 2002; 94: 116-28
48. O'Brien N, Maguire T, O'Donovan N, Lynch N, Hill AD, McDermott E, et al. Mammaglobin A: a promising marker for breast cancer. Clin Chem 2002; 48: 1362-4
49. Woolas RP, Xu FJ, Jacobs IJ, Yu YH, Daly L, Berchuck A, et al. Elevation of multiple serum markers in patients with stage I ovarian cancer. J Natl Cancer Instit 1993; 85: 1748-51
50. Smith SD, Wheeler MA, Plescia J, Colberg JW, Weiss RM, Altieri DC. Urine detection of survivin and diagnosis of bladder cancer. JAMA 2001; 285: 324-8
51. de Kok JB, Verhaegh GW, Roelofs RW, Hessels D, Kiemeney LA, Aalers TW, et al. DD3PCA3, a very sensitive and specific marker to detect prostate tumors. Cancer Res 2002; 62: 2695-8